Entrada Therapeutics (TRDA) Revenue (2023 - 2026)

Entrada Therapeutics' Revenue history runs 4 years deep, the most recent figure standing at $875000.0 for Q1 2026.

• On a quarterly basis, Revenue fell 95.74% year-over-year to $875000.0 in Q1 2026; TTM through Mar 2026 was $5.7 million, a 96.67% decrease from a year earlier, with the FY2025 full-year figure at $25.4 million, down 87.94% from the prior year.
• Revenue declined to $875000.0 in Q1 2026 per TRDA's latest filing, from $1.3 million in the prior quarter.
• Across five years, Revenue topped out at $94.7 million in Q2 2024 and bottomed at $875000.0 in Q1 2026.
• The 4-year median for Revenue is $20.6 million (2025), against an average of $28.2 million.
• Across the five-year window, Revenue soared 421.16% in 2024 and slumped 97.94% in 2025, its largest moves.
• Year by year, Revenue stood at $41.8 million in 2023, then dropped by 10.63% to $37.4 million in 2024, then sank by 96.53% to $1.3 million in 2025, then plunged by 32.64% to $875000.0 in 2026.
• Per Business Quant, the three latest TRDA Revenue figures stand at $875000.0 (Q1 2026), $1.3 million (Q4 2025), and $1.6 million (Q3 2025).